Form 4: Agenus CEO Garo Armen Receives Stock in Lieu of Cash Salary

Agenus CEO Garo Armen received 4,769 shares of common stock as part of his salary for the pay period ending November 29, 2024.

Summary

• Garo H. Armen, CEO of Agenus Inc., received 4,769 shares of common stock as part of his salary in lieu of cash.
• The stock was issued at a price of $3.42 per share, which was the closing price of Agenus common stock on November 29, 2024.
• These shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive and are fully vested upon issuance.
• Mr. Armen also indirectly owns 31,298 shares through IRA accounts and 28,950 shares through a trust and partnership.
• The transaction was reported on a Form 4 filing with the SEC.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed neutrally to slightly positive as it aligns management with shareholders.

Positives

• The CEO's decision to take stock in lieu of cash may signal confidence in the company's future performance.
• The shares are fully vested upon issuance, aligning the CEO's interests with shareholders.

Management Comments

• Garo H. Armen's salary is being paid in stock, in lieu of cash, at his request and with the approval of the Agenus Inc. Compensation Committee.

Industry Context

This type of transaction, where executives receive stock as part of their compensation, is common in the biotech industry and can be seen as a way to align management's interests with those of shareholders.

Comparison to Industry Standards

• Many biotech companies use stock-based compensation to attract and retain talent, particularly at the executive level.
• This practice is similar to other companies in the sector, such as Moderna and BioNTech, which also use stock options and grants as part of their compensation packages.

Stakeholder Impact

• Shareholders may view the CEO taking stock in lieu of cash as a positive sign of confidence in the company's future.

Key Dates

Keywords

Agenus, Garo Armen, stock, salary, equity, Form 4, SEC, beneficial ownership